- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
MoAb firm Cytogen to acquire Cellcor
Monoclonal antibody developer Cytogen of Princeton, NJ, has signeda definitive agreement to acquire Cellcor, a biotechnology firmbased in Newton, MA, that is developing a technique called autolymphocytetherapy (ALT), which uses a patient's immune cells
Monoclonal antibody developer Cytogen of Princeton, NJ, has signeda definitive agreement to acquire Cellcor, a biotechnology firmbased in Newton, MA, that is developing a technique called autolymphocytetherapy (ALT), which uses a patient's immune cells to treat cancerand infectious diseases. Cellcor's first product, for treatingrenal cell carcinoma, is in phase III clinical studies.
The transaction will be handled through a stock swap, withCellcor shareholders receiving 0.6 shares of Cytogen stock foreach of the 5.5 million shares of Cellcor common stock. The dealwas valued at $19.5 million by analysts, who said Cellcor wasdown to its last month of cash.
In other Cytogen news, the company filed a new drug application(NDA) with the Food and Drug Administration for Quadramet, a samarium-153-basedagent for the treatment of pain due to cancer that has spreadto the bone. Cytogen has licensed U.S. marketing and manufacturingrights for Quadramet to Du Pont Merck.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
